Caris Life Sciences

NSQ:CAI · US1421521071

BiotechnologySmall

360

Value50

Profit price7

EV / EBIT12

Price / Owner Earnings1

Cash yield37

Owner Earnings Yield73

Dividend Yield1

Sales & asset price53

Price/Sales49

EV / Gross Profit78

Price/Book33

Quality79

Returns on capital84

Return on Capital90

Cash Return on Capital73

Return on Equity90

Profit margins74

EBIT Margin59

Gross Profitability88

Cash backing78

Cash Conversion100

Accruals73

Owner Earnings Margin61

Growth58

Sales growth57

Profit growth76

Profit Growth65

Long-Term EPS Growth86

Reinvestment97

Price momentum18

Safety56

Debt load41

Debt serviceability81

Refinancing62

Debt Payback100

Liquidity64

Sentiment59

Analyst ratings44

Expectations trend54

Opinion Changes50

Price Target Upside57

Market mood71

Value Creation16/20strong value creator

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Caris Life Sciences generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2011

Employees1,452

Websitecarislifesciences.com

ISINUS1421521071

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

Machine LearningHematologyHealth DiagnosticsGeneticsOncologyArtificial IntelligenceBiotechnologyHealth CareMedical

Description

Caris Life Sciences, Inc. operates as a patient-centric, next-generation AI TechBio company. The company develops and commercializes innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial in…

Analysis

Quality compounder

Caris Life Sciences, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is expensive. You pay 165.2× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 35% yearly growth; analysts expect 37%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is adequate. The company scores 16/20 on our value-creation score: strong value creator.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Caris Life Sciences with its peers

Roadzen

NMQ:RDZN

CountryUSA

IndustrySoftware

SizeSmall

Full Stock Analysis →

Natera

NSQ:NTRA

CountryUSA

IndustryBiotechnology

SizeLarge

Full Stock Analysis →

Kodiak AI

NMQ:KDK

CountryUSA

IndustryAuto Components

SizeSmall

Full Stock Analysis →

Pulse Biosciences

NAQ:PLSE

CountryUSA

IndustryHealth Care Equipment & Supplies

SizeSmall

Full Stock Analysis →

Myriad Genetics

NSQ:MYGN

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

AMC Robotics

NAQ:AMCI

CountryUSA

IndustryElectronic Equipment, Instruments & Components

SizeX-Small

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →